268 related articles for article (PubMed ID: 1819976)
21. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.
Bonadonna G; Viviani S; Bonfante V; Gianni AM; Valagussa P
Eur J Cancer; 2005 May; 41(7):998-1006. PubMed ID: 15862748
[TBL] [Abstract][Full Text] [Related]
22. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F
Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373
[TBL] [Abstract][Full Text] [Related]
23. Treatment of advanced Hodgkin's disease: 10-year experience in the Eastern Cooperative Oncology group.
Glick JH; Barnes JM; Bakemeier RF; Prosnitz LR; Bennett JM; Neiman RS; Costello W; Orlow EL
Cancer Treat Rep; 1982 Apr; 66(4):855-70. PubMed ID: 7042087
[TBL] [Abstract][Full Text] [Related]
24. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
[TBL] [Abstract][Full Text] [Related]
25. Pediatric Hodgkin's disease.
Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
[TBL] [Abstract][Full Text] [Related]
26. ChlVPP--an effective and well-tolerated alternative to MOPP therapy for Hodgkin's disease.
Vose J; Armitage J; Weisenburger D; Moravec D; Hutchins M; Howe D; Sorensen S; Dowling M; Okerbloom J; Pevnick W
Am J Clin Oncol; 1988 Aug; 11(4):423-6. PubMed ID: 3407620
[TBL] [Abstract][Full Text] [Related]
27. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial.
Longo DL; Glatstein E; Duffey PL; Young RC; Hubbard SM; Urba WJ; Wesley MN; Raubitschek A; Jaffe ES; Wiernik PH
J Clin Oncol; 1991 Jun; 9(6):906-17. PubMed ID: 2033427
[TBL] [Abstract][Full Text] [Related]
28. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
Longo DL; Duffey PL; DeVita VT; Wiernik PH; Hubbard SM; Phares JC; Bastian AW; Jaffe ES; Young RC
J Clin Oncol; 1991 Aug; 9(8):1409-20. PubMed ID: 1712836
[TBL] [Abstract][Full Text] [Related]
29. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
Bakemeier RF; Anderson JR; Costello W; Rosner G; Horton J; Glick JH; Hines JD; Berard CW; DeVita VT
Ann Intern Med; 1984 Oct; 101(4):447-56. PubMed ID: 6089632
[TBL] [Abstract][Full Text] [Related]
30. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease.
Klimo P; Connors JM
J Clin Oncol; 1985 Sep; 3(9):1174-82. PubMed ID: 2411881
[TBL] [Abstract][Full Text] [Related]
31. Chlorambucil, vinblastine, procarbazine, and prednisone. An effective but less toxic regimen than MOPP for advanced-stage Hodgkin's disease.
Druker BJ; Rosenthal DS; Canellos GP
Cancer; 1989 Mar; 63(6):1060-4. PubMed ID: 2917308
[TBL] [Abstract][Full Text] [Related]
32. [Chemotherapy of advanced lymphogranulomatosis. Results of MOPP/COPP treatment at the West German Tumor Center, Essen].
Höffken K; Ippisch A; Pfeiffer R; Becher R; Seeber S; Schmidt CG
Dtsch Med Wochenschr; 1985 Apr; 110(16):618-23. PubMed ID: 3838719
[TBL] [Abstract][Full Text] [Related]
33. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study.
Biti GP; Cimino G; Cartoni C; Magrini SM; Anselmo AP; Enrici RM; Bellesi GP; Bosi A; Papa G; Giannarelli D
J Clin Oncol; 1992 Mar; 10(3):378-82. PubMed ID: 1740677
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease.
Tannir N; Hagemeister F; Velasquez W; Cabanillas F
J Clin Oncol; 1983 Jul; 1(7):432-9. PubMed ID: 6199478
[TBL] [Abstract][Full Text] [Related]
35. Twenty years of MOPP therapy for Hodgkin's disease.
Longo DL; Young RC; Wesley M; Hubbard SM; Duffey PL; Jaffe ES; DeVita VT
J Clin Oncol; 1986 Sep; 4(9):1295-306. PubMed ID: 3528400
[TBL] [Abstract][Full Text] [Related]
36. Hodgkin's disease and acute leukemia. Is it a true association?
Avilés A; Díaz-Maqueo JC; Ayala JR; Cortés HD; García EL
Arch Med Res; 1992; 23(1):65-8. PubMed ID: 1308794
[TBL] [Abstract][Full Text] [Related]
37. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.
Longo DL; Russo A; Duffey PL; Hubbard SM; Glatstein E; Hill JB; Jaffe ES; Young RC; DeVita VT
J Clin Oncol; 1991 Feb; 9(2):227-35. PubMed ID: 1988570
[TBL] [Abstract][Full Text] [Related]
38. [ Long-term evaluation of the effect of a chemotherapy protocol using vincristine, adriamycin, procarbazine and prednisone (VAPP) on advanced Hodgkin's disease].
Marinone G; Colle R; Mombelloni P
Minerva Med; 1978 Apr; 69(18):1255-61. PubMed ID: 662153
[TBL] [Abstract][Full Text] [Related]
39. The role of MOPP chemotherapy in early stage Hodgkin's disease.
Mauch P; Hellman S
Hematol Oncol; 1984; 2(1):66-9. PubMed ID: 6376318
[No Abstract] [Full Text] [Related]
40. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease.
Radford JA; Crowther D; Rohatiner AZ; Ryder WD; Gupta RK; Oza A; Deakin DP; Arnott S; Wilkinson PM; James RD
J Clin Oncol; 1995 Sep; 13(9):2379-85. PubMed ID: 7666097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
